Veröffentlichungen
Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis. Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications and Prognostic Value of Peritoneal Carcinomatosis.
P. Harter, M. Hahmann, H. J. Lück, M. Poelcher, P. Wimberger, O. Ortmann, U. Canzler, B. Richter, U. Wagner, A. Hasenburg, A. Burges, S. Loibl, W. Meier, J. Huober, D. Fink, W. Schröder, K. Münstedt, B. Schmalfeldt, G. Emons, A. du Bois
Ann Surg Oncol, 2009
Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis Exploratory Analysis oft he DESKTOP I Trial About Risk Factors, Surgical Implications and Prognostic Value of Peritoneal Carcinomatosis.
P. Harter, M. Hahmann, H. J. Lück, M. Poelcher, P. Wimberger, O. Ortmann, U. Canzler, B. Richter, U. Wagner, A. Hasenburg, A. Burges, S. Loibl, W. Meier, J. Huober, D. Fink, W. Schröder, K. Münstedt, B. Schmalfeldt, G. Emons, A. du Bois
Ann Surg Oncol 2009
Predictive factors for resection in recurrent ovarian cancer (ROC) Intergroup Study of AGO Kommission OVAR, AGO-OVAR, AGO Austria, MITO and NOGGO
W. Schröder, P. Harter, A. Reuss, G. Cormio, A. du Bois
Int J Gynaecol Obstet 2009
Topotecan weekly versus conventional five-day schedule in patients with platinum-resistant ovarian Cancer (TOWER). A randomized multi-center phase II trial of the NOGGO Ovarian Cancer Study Group.
J. Sehouli, D. Stengel, P. Harter, C. Kurzeder, A. Belau, T. Bogenrieder, S. Markmann, S. Mahner, L. Mueller, R. Lorenz, A. Nugent, J. Wilke, A. Kuznik, G. Doering, A. Wischnik, H. Sommer, H. G. Meerpohl, W. Schroeder, W. Lichtenegger, G. Oskay-Oezcelik
JCO Jan 2011
Combination therapy with pegliposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal gynecologic tumours. A prospective multicenter phase-II trial of the AGO-Group
S. Mahner, A. Du Bois, J. Sehouli, A. Reuss, K. Baumann, L. C. Hanker, P. Wimberger, W. Schröder, M. Gropp, P. Harter
Onkologie 2010
Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumours. A phase-II trial o the AGO Sutdy Group.
P. Harter, U. Canzler, H. J. Lück, A. Reuss, W. Meier, T. Fehm, A. Stähle, A. Burges, C. Kurzeder, J. Sehouli, K. Baumann, L. Hanker, P. Wimberger, W. Schröder, M. Gropp, S. Mahner, A. du Bois
JCO 29, 2011
Retrospective Multicenter outcome survey in Borderline Ovarian Tumors (ROBOT; AFO-OVAR OP.5). A Study of the AGO Study Group.
A. du Bois, M.-D. Keyver, K. Baumann, A. Reuss, U. Canzler, K. Wollschlaeger, F. Kommoss, D. Forner, M. Peters, W. Schröder, K. Münstedt, B. Richter, N. Ewald-Riegler, N. De Gregorio, S. Mahner, C. Fotopoulou, B. Schmalfeldt, F. Hilpert, T. Fehm, A. Burges, W. Meier, P. Hillemanns, L. Hanker, A. Hasenburg, H.-G. Strauss, M. Hellriegel, P. Wimberger, S. Kommoss, S. Hauptmann
ESGO 2011
Development and validation of a Nomogram to Predict suvival in Calypso and AGO-2.5 Patients with Platinum sensitive recurrent Ovarian Cancer
C. Lee, J. Simes, V. Gebski, K. Wollschlaeger, M. Plante, I. Vergote, J. Mäenpäa, A.-M. Ferrero, C. Pisano, G. Parma, D. Berton-Rigaud, W. Schröder, J. Bentley, A. Reinthaller, B. Schmalfeldt, H. Hirte, J. Pfisterer, E. Pujade-Lauraine, M. Friedlander
ESGO 2011
Diagnostik und Therapie maligner Ovarialtumoren.
W. Schröder
OVAR 10 ABA01/MIMOSA Maintencance Abagovomab vs. Placebo
Mahner S, Harter P, Sehouli J, Meier W, Wimberger P, de Gregorio N, Hasenburg A, Baumann K, Schmalfeldt B, Hanker L, Solomayer E, Stähle A, Beckmann MW, Canzler U, Burges A, Wollschlaeger K, Hillemanns P, Jackisch C, Hilpert F, Emons G, Schröder W, Belau A, Richter B, Pfisterer J.
DKK 2012
ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.
Oza AM, Perren TJ, Swart AM, Schröder W, Pujade-Lauraine E, Havsteen H, Beale P, Cervantes A, Embleton AC, Parmar M on behalf of the ICON7 investigators (MRC/NCRI, AGO-OVAR, GINECO, NSGO, ANZGOG, GEICO, NCIC-CTG)
ECCO-ESMO 2013
Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV
Meier W, du Bois A, Rau J, Gropp M, Baumann KH, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schröder W, Belau A, Stähle A, Burges A, Sehouli J
Gynecologic Oncology 2012
Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial
Kurzeder Ch, Meier W, Jackisch Ch, Stähle A, Burges A, Pfisterer J, Belau A, Emons G, Canzler U, Schröder W, Sehouli J, du Bois A, Wimberger P, Schmalfeldt B, Mahner S, Wagner U, Pujade-Lauraine E.
DKK 2012
Topotecan plus Carboplatin im Vergleich zur Standardtherapie mit Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertem liposomalem Doxorubicin plus Carboplatin: Eine randomisiertePhase-III-Studie der AGO und NOGGO mit internationaler Beteiligung (AGO-Österreich, GEICO) – HECTOR/ AGO-OVAR 2.12.
Canzler U, Chekerov R, Burges A, Hasenburg A, Emons G, Reimer T, Lorenz R, Behringer D, Müller L, Ulmer HU, Schröder W, Achtert I, Sommer H, Kuznik A, Heinrich G, Sehouli J
Abstrakt für DGGG 2012
Topotecan-Carboplatin versus standard Platinum combinations in patients with Platinum-Sensitive recurrent ovarian cancer- The GCIG Intergroup - ‘HECTOR’ Phase III Trial
Mahner S, Chekerov R, Zeimet A, Garcia-Martinez E, Hanker L, Klare P, Denison U, Burges A, Dörfel S, Hasenburg A, Richter R, Strauss HG, Emons G, Schröder W, Meier W, Sehouli J, NOGGO, AGO-Germany, AGO-Austria, GEICO, GCIG
Abstrakt für IGCS 2012
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial- Mesenchymal Tumors. A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)
Harter P, Sehouli J. Reuss A, Baumann K, Hanker L, Kimmig R, Schröder W, Burges A, Gropp-Meier M, Kurzeder Ch, Mahner S, Canzler U, Lück HJ, Meier W
Int J Gynecol Cancer, 2015
Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN)
Emons G, Kurzeder C, Schmalfeldt B, Reuss A, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner M, Hanker L, Thiel F, Hilpert F
Abstract Submission für ASCO 2014
Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)
Hilpert F, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner M, Hanker L, Thiel F, Emons G
DGGG 2014
Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)
Hilpert F, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner M, Hanker L, Thiel F, Emons G
IGCS 2014
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-Study Group (AGO-GYN8)
Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner MH, Hanker L, Thiel F, Hilpert F
Gynecologic Oncology submitted 11/2015
Pegylated liposomal doxorubicin (PLD) and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors. A meta-analysis of three prospective AGO Study Group trials
Harter P, Reuss A, Hanker L, Sehouli J, Baumann K, Meier W, Wimberger P, Schröder W, Burges A, du Bois A.
DKK 2012
Pegylated liposomal doxorubicin (PLD) and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors. A meta-analysis of three prospective AGO Study Group trials
Schröder W, du Bois A, Reuß A, Pfisterer J, Hanker L, Sehouli J, Baumann K, Meier W, Wimberger P, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Fehm T, Canzler U, Lück HJ, Harter P
IGCS 2012
A semi prospective trial to determine the outcome of borderline ovarian tumor patients. Results of the ROBOT study, a study of the AGO study group
de Gregorio N, Baumann K, Keyver-Paik MD, Reuß A, Canzler U, Wollschlaeger K, Kommoss F, Forner D, Peters M, Schröder W, Münstedt K, Richter B, Ewald-Riegler N, Mahner S, Fotopoulou C, Schmalfeldt B, Hilpert F, Kommoss S, Hauptmann S, du Bois A
J Clin Oncol 2012
Retrospective multicenter outcome survey in borderline ovarian tumors (ROBOT; AGO-OVAR OP.5). A study of the AGO study group
Hanker L, Keyver-Paik M-D, Baumann K, Reuss A, Canzler U, Wollschlaeger K, Kommoss F, Forner D, Peters M, Schröder W, Münstedt C, Richter B, Burges A, Fehm T, Meier W, Hillemanns P, Hasenburg A, Strauss H.-G, Hauptmann S, du Bois A
DGGG 2012
Prospective Study of Borderline tumors of the ovary: Role of prognostic marker and clinical outcome. A project of AGO Study Group
Sehouli J, Canzler U, Wollschlager K, Reuss A, Forner D, Peters M, Kommoss F, Schröder W, Münstedt K, Richter B, Ewald-Riegler N, de Gregorio N, Mahner S, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hauptmann S, Hillemanns P, Hanker L, Hasenburg A, Strauß HG, Hellriegel M, Wimberger P, Kommoss S, Baumann K, Keyver-Paik MD, du Bois A
IGCS 2012
Borderline tumors of the ovary: A cohort study of the AGO study group
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S. for the AGO Study Group
European Journal of Cancer 2013
Results of the Retrospective multicenter Outcome survey in Borderline Ovarian Tumors of the AGO Study Group
Hauptmann S, Kommoss F, Ewald-Riegler N, Reuss A, de Gregorio N, Mahner S, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, du Bois A
DGP 2014
Prognostic impact of the time interval between primary and re-staging surgery in patients with borderline ovarian tumours (BOT): An analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group
Trillsch F, Mahner S, Ruetzel JD, Vettorazzi E, Reuß A, Hillemanns P, Hanker L, Hasenburg A, Strauß HG, Hellriegel M, Wimberger P, Klaus B, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Fehm T, Meier W, Ewald-Riegler N, de Gregorio N, Hilpert F, du Bois A
DKK 2014 Abstrakt 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: A sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT Study
Trillsch F, Mahner, S, Woelber L, Vettarazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik DM, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss F, Hauptmann S, Andreas du Bois
Annals of Oncology 2014
Prognostische Bedeutung von Zeitintervall und Staging-Prozeduren für Patientinnen mit primären Borderline-Tumoren des Ovars (BOT): Eine Subgruppen-Analyse der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ROBOT- Studi
Trillsch F, Mahner S, Wölber L, Vettorazzi E, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauß HG, Hellriegel M, Wimberger P, du Bois A
DGGG 2014
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study Running title: Surgical staging and prognosis in serous BOT
Trillsch F, Mahner S, Vettorazzi E, Wölber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauß HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A
British Journal of Cancer 2015
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
Emons G., Kurzeder C., Schmalfeldt B., Neuser P., de Gregorio N., Pfisterer J., Park-Simon TW., Mahner S., Schröder W., Lück HJ., Heuber ML., Hanker L., Thiel F., Hilpert.,
Gynecol Oncol 2015
> 250 zitierfähige wissenschaftliche Veröffentlichungen in nationalen und internationalen Fachzeitschriften bis 12/2008.
